Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Interest & Investment Income of $1.8 million for Q1 2026, up 239.81% year-over-year from $525000.0 in Q1 2025, and up 141.73% quarter-over-quarter from $738000.0 in Q3 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 239.81% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $3.7 million (up 100.22% YoY), while the FY2023 annual figure was $1.6 million, up 142.2% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.8 million, up from $738000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.8 million in Q1 2026, with the low at $11000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $403000.0 (2023), against an average of $482666.7.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 9900.0% in 2022, then dropped 15.96% in 2024.
- Corvus Pharmaceuticals' Interest & Investment Income stood at $318000.0 in 2022, then rose by 19.5% to $380000.0 in 2023, then surged by 48.95% to $566000.0 in 2024, then jumped by 30.39% to $738000.0 in 2025, then soared by 141.73% to $1.8 million in 2026.
- Business Quant data shows CRVS's Interest & Investment Income at $1.8 million in Q1 2026, $738000.0 in Q3 2025, and $639000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Corvus Pharmaceuticals | 1.35 Bn | 1.14 Bn | - | 2.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Mar 31, 2026 | 1.78 Mn |
| Sep 30, 2025 | 738,000.00 |
| Jun 30, 2025 | 639,000.00 |
| Mar 31, 2025 | 525,000.00 |
| Sep 30, 2024 | 566,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 316,000.00 |
| Dec 31, 2023 | 380,000.00 |
| Sep 30, 2023 | 425,000.00 |
| Jun 30, 2023 | 403,000.00 |
| Mar 31, 2023 | 376,000.00 |
| Dec 31, 2022 | 318,000.00 |
| Sep 30, 2022 | 225,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 11,000.00 |
| Dec 31, 2021 | -8,000.00 |
| Sep 30, 2021 | -11,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 3,000.00 |